<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00250419</url>
  </required_header>
  <id_info>
    <org_study_id>V930-002</org_study_id>
    <secondary_id>2005_047</secondary_id>
    <nct_id>NCT00250419</nct_id>
  </id_info>
  <brief_title>V930 First in Man (FIM) Study (V930-002)(COMPLETED)</brief_title>
  <official_title>A Phase I Study to Evaluate the Safety/Tolerability and Immunogenicity of V-930 in Patients With Cancers Expressing HER-2 and/or CEA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      To determine the safety/tolerability, and immunogenicity of an experimental vaccine given as
      intramuscular injections followed by electrostimulation in cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">26</enrollment>
  <condition>Cancers Expressing HER-2 and/or CEA</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V930</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have stages II, III, or IV breast, colorectal, ovaria, of non-small cell
             lung cancer

          -  Patients will either be disease free following primary therapy or have advanced
             disease with a durable response (&gt;3 months) after standard therapy

          -  Tumor antigen HER-2 and/or CEA must be measurable in the blood or detected by
             Immunohistochemistry staining of the biopsies obtained from the primary tumor or
             metastasis

        Exclusion Criteria:

          -  Patients with prior treatment with any HER-2 and/or CEA containing vaccine

          -  Patients who have significant cardiac disease

          -  Patients with autoimmune disorders

          -  Patients who are pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Italy</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2005</study_first_submitted>
  <study_first_submitted_qc>November 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2005</study_first_posted>
  <last_update_submitted>February 9, 2015</last_update_submitted>
  <last_update_submitted_qc>February 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

